Investors Should Take Note Of Allena Pharmaceuticals Inc. (ALNA)


After grabbing 2.79 million shares, the institutional investor is now in possession of 2.79 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 7.33% having worth around $3.46 million. Moreover, Sabby Capital LLC increased its share by 1.53 million to have a control over 1.53 million shares. And BBVA Asset Management SA SGIIC raised its holdings to 0.4 million shares by acquiring 0.75 million shares or 1.96% of the stake.

Allena Pharmaceuticals Inc. (ALNA) concluded trading on 08/27/20 at a closing price of $1.44, with 1.97 million shares of worth about $2.84 million changed hands on the day. Weekly performance of the stock remained positive as price took a surge of 2.13% during that period and on Thursday the price saw a gain of about 2.86%. Currently the company’s common shares owned by public are about 37.95M shares, out of which, 27.66M shares are available for trading.

A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the ALNA stock and their offered price forecasts bring an average price target of $8.40. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $18.00 and could fall to a lowest price of $1.00. Analysts also issued an outlook of 1.70 for the Allena Pharmaceuticals Inc. stock for next 12 months. However, touching the estimated high of $18.00 would mean a gain of 92.0% for the stock.

According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.

Vifag 2002, SICAV, FCP Medical – BioHealth, and Vanguard Total Stock Market Index are the top 3 mutual funds which are holding stakes in Allena Pharmaceuticals Inc. Vifag 2002, SICAV is currently holding 0.7 million shares of worth totaling $0.87 million. The company recently came buying 0.35 million shares which brought its stake up to 1.83% of the company’s outstanding shares. FCP Medical – BioHealth bought 0.28 million shares, after which its hold over company’s outstanding shares expand to 1.02%, leaving 0.39 million shares with the mutual fund that have a worth of about $0.48 million. Vanguard Total Stock Market Index, after buying 0.25 million shares, have now control over 0.64% of the stake in the company. It holds 0.0 shares of worth $0.3 million.

Allena Pharmaceuticals Inc. (NASDAQ: ALNA) started trading at $1.40, below $0.0 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $1.44, or with a gain of 2.86%. Stock saw a price change of 2.13% in past 5 days and over the past one month there was a price change of 13.39%. Year-to-date (YTD), ALNA shares are showing a performance of -47.25% which decreased to -66.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.52 but also hit the highest price of $6.30 during that period. While comparing its average daily trading volume of 1.50 million shares, we see that about 1.97 million changed hands on the day. The stock is currently trading 2.31% above its 20-day simple moving average (SMA20), while that difference is down -4.95% for SMA50 and it goes to -20.66% lower than SMA200.

Empery Asset Management LP acquired 2.79 million shares of Allena Pharmaceuticals Inc. having value of about $3.46 million. Allena Pharmaceuticals Inc. (NASDAQ: ALNA) currently have 37.95M outstanding shares and institutions hold larger chunk of about 45.60% of that. Holding of mutual funds in the company is about 30.51% while other institutional holders and individual stake holders have control over 5.63% and 22.86% of the stake respectively.

The stock has a current market capitalization of $56.03M. It has posted earnings per share of -$1.62 in the same period. It has Quick Ratio of 4.20 while making debt-to-equity ratio of 0.43. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALNA, volatility over the week remained 11.36% while standing at 9.93% over the month.

Analysts are in expectations that Allena Pharmaceuticals Inc. (ALNA) stock would likely to be making an EPS of -$0.22 in the current quarter, while forecast for next quarter ESPS is -$0.21 and it is -$0.81 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.26 which is -$0.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.57 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -24.20% while it is estimated to increase by 6.40% in next year.

Analysts at 6 brokerage firms have issued recommendations for the Allena Pharmaceuticals Inc. (ALNA)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.70. Out of those 6 Wall Street analysts, 5 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 01, 2020 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Credit Suisse stated Allena Pharmaceuticals Inc. (ALNA) stock as an Outperform in their note to investors on July 10, 2019, suggesting a price target of for the stock. On January 18, 2019, Robert W. Baird Initiated their recommendations, while on December 21, 2018, B. Riley FBR Resumed their ratings for the stock with a price target of. Stock get a Buy rating from Jefferies on November 08, 2018.


Please enter your comment!
Please enter your name here